drugset / Trial / NCT00604279
A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the efficacy of paliperidone palmitate and risperidone long acting injection (LAI) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) along with safety and tolerability.
Timeline
- Start
- 2008-01
- Primary completion
- 2009-01
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Risperidone | Other / unclassified | 1 mg | Intramuscular |
| Comparator | Risperidone | Other / unclassified | 2 mg | Intramuscular |
| Comparator | Risperidone | Other / unclassified | 6 mg | Intramuscular |
| Comparator | Risperidone | Other / unclassified | 25 mg | Intramuscular |
| Comparator | Risperidone | Other / unclassified | 37.5 mg | Intramuscular |
| Comparator | Risperidone | Other / unclassified | 50 mg | Intramuscular |
| Subject | paliperidone palmitate | Unknown | 50 mg | Intramuscular |
| Subject | paliperidone palmitate | Unknown | 100 mg | Intramuscular |
| Subject | paliperidone palmitate | Unknown | 150 mg | Intramuscular |